ProQR Therapeutics N.V. filings document a Nasdaq-listed foreign private issuer furnishing Form 6-K current reports for its RNA therapeutics business. The disclosures describe the Axiomer RNA editing platform, ADAR-mediated oligonucleotide design, pipeline programs including AX-0810, AX-2402 and AX-2911, scientific presentations, collaborations, and annual operating and financial results.
The filing record also covers governance and capital-market matters, including annual general meeting notices, agenda materials, proxy forms, proposed articles-of-association amendments, board nominations and board-composition updates. Several Form 6-K reports incorporate company materials by reference into Form F-3 registration statements, linking current business updates with registered securities disclosure.
ProQR Therapeutics reported first quarter 2026 results showing continued investment in its RNA editing pipeline and a larger loss. Revenue was €2.0 million, down from €4.5 million a year earlier, mainly from its collaboration with Eli Lilly. The company recorded a net loss of €13.4 million, or €0.13 per share, versus €10.1 million, or €0.10 per share, in 2025, driven by R&D of €11.8 million and G&A of €3.9 million.
Cash and cash equivalents were €81.1 million at March 31, 2026, compared with €92.4 million at year-end 2025, with net cash used in operating activities of €11.1 million. Management states this cash provides funding into at least the twelve months following issuance and, in forward-looking commentary, indicates a runway into mid 2027. Operationally, ProQR is advancing its Axiomer RNA editing platform, with lead program AX‑0810 on track for target engagement data in healthy volunteers in the second quarter of 2026 and an investigator-initiated biliary atresia trial in China planned ahead of Phase 2 development.
ProQR Therapeutics reported first quarter 2026 results and provided a pipeline update centered on its Axiomer RNA editing platform. Revenue was €2.0 million, down from €4.5 million a year earlier, and the company recorded a net loss of €13.4 million, or €0.13 per diluted share, versus a €10.1 million loss, or €0.10 per share, in 2025.
Cash and cash equivalents were €81.1 million at March 31, 2026 compared with €92.4 million at year-end 2025, with net cash used in operating activities of €11.1 million, improving from €15.8 million in the prior-year quarter. Lead program AX-0810 remains on track for target engagement data in the second quarter of 2026, and an investigator-initiated biliary atresia trial in China is planned with initial data targeted for the first half of 2027.
ProQR Therapeutics N.V. has called its 2026 Annual General Meeting for June 2, 2026 at 15:00 CEST in Amsterdam. Shareholders of record on May 5, 2026 may attend and vote.
The agenda includes adopting the 2025 annual accounts, releasing board members from liability for 2025, appointing Dr. Lykke Hinsch Gylvin as a new non-executive director for a four-year term, and appointing KPMG Accountants N.V. as external auditor for 2027.
Shareholders are also asked to approve an amendment of the articles to increase the authorized capital so each of the ordinary and preferred share classes has an authorized share capital of 270,000,000 shares, renew a five-year authorization for the board to issue ordinary shares up to 100% of authorized capital (with equity plans capped at 15% of issued capital), and authorize the board for 18 months to repurchase up to 10% of issued shares, plus an additional 10% in case of a material capital reorganization, at prices between US$0.01 and up to 110% of the average Nasdaq market price.
ProQR Therapeutics, a clinical-stage company focused on RNA therapies using its Axiomer™ RNA editing platform, has nominated Dr. Lykke Hinsch Gylvin to its Board of Directors. She is Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim and has over 20 years of global pharmaceutical leadership experience.
The nomination will be submitted for shareholder approval at ProQR’s upcoming Annual General Meeting. If approved, Dr. Hinsch Gylvin will serve as an independent non-executive director, bringing broad drug development, regulatory, and medical affairs experience from roles at Boehringer Ingelheim, Novartis, AstraZeneca, Roche, Novo Nordisk, and Lundbeck.
ProQR Therapeutics used a virtual analyst and investor event to showcase progress on its Axiomer RNA editing pipeline and outline upcoming clinical milestones. The lead program, AX-0810 targeting NTCP, is expected to deliver target engagement data from healthy volunteers in the first half of 2026, with biliary atresia chosen as the initial Phase 2 indication based on biological rationale and unmet need. The company also announced two new programs, AX-0811 and AX-0422, and highlighted additional candidates such as AX-2911 and AX-2402 as part of a growing portfolio. ProQR emphasized AI-enabled discovery, high-throughput screening, and its partnership with Ginkgo Bioworks to design and optimize RNA editing therapeutics. Management stated that multiple clinical data readouts are expected across the pipeline within its current cash runway, which extends into mid-2027.
ProQR Therapeutics used a virtual analyst and investor event to showcase progress on its Axiomer RNA editing pipeline and outline upcoming clinical milestones. The lead program, AX-0810 targeting NTCP, is expected to deliver target engagement data from healthy volunteers in the first half of 2026, with biliary atresia chosen as the initial Phase 2 indication based on biological rationale and unmet need. The company also announced two new programs, AX-0811 and AX-0422, and highlighted additional candidates such as AX-2911 and AX-2402 as part of a growing portfolio. ProQR emphasized AI-enabled discovery, high-throughput screening, and its partnership with Ginkgo Bioworks to design and optimize RNA editing therapeutics. Management stated that multiple clinical data readouts are expected across the pipeline within its current cash runway, which extends into mid-2027.
ProQR Therapeutics announced an AI-focused strategy for its Axiomer™ RNA editing platform, highlighted by a new partnership with Ginkgo Bioworks and the creation of an AI Advisory Board. Ginkgo is providing access to its 50+ instrument autonomous lab, Nebula, and has made a strategic equity investment in ProQR.
ProQR plans to move its first AI-enabled RNA editing programs into the clinic, with a clinical trial application targeted for mid-2026 and initial clinical data anticipated by year-end 2026. The company is also hosting a virtual Investor and Analyst event to present broader pipeline updates, new programs with upcoming clinical readouts, and the primary indication for AX-0810.
ProQR Therapeutics announced an AI-focused strategy for its Axiomer™ RNA editing platform, highlighted by a new partnership with Ginkgo Bioworks and the creation of an AI Advisory Board. Ginkgo is providing access to its 50+ instrument autonomous lab, Nebula, and has made a strategic equity investment in ProQR.
ProQR plans to move its first AI-enabled RNA editing programs into the clinic, with a clinical trial application targeted for mid-2026 and initial clinical data anticipated by year-end 2026. The company is also hosting a virtual Investor and Analyst event to present broader pipeline updates, new programs with upcoming clinical readouts, and the primary indication for AX-0810.
ProQR Therapeutics N.V. has scheduled a virtual Investor and Analyst Event for April 8, 2026, titled “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810.” The event will highlight its broader RNA editing pipeline, introduce new programs with upcoming clinical data, and unveil the primary indication for lead candidate AX-0810.
The company reiterates its focus on its proprietary Axiomer™ RNA base editing platform, which uses the body’s own ADAR enzymes to make single-nucleotide edits in RNA that may correct disease-causing mutations or modulate protein expression. ProQR also reminds readers of anticipated target engagement data for AX-0810 in the first half of 2026 and additional clinical updates across multiple programs during 2026.
ProQR Therapeutics N.V. director Valerio Domenico filed an initial ownership report showing his equity position in the company. He directly holds 420,729 Ordinary Shares and has additional indirect exposure through a Valerio family foundation, for which he disclaims beneficial ownership except for any pecuniary interest.
He also holds multiple employee share options over Ordinary Shares with exercise prices ranging from $1.98 to $15.78 per share and expiration dates between 2026 and 2035. These options give him rights to buy additional shares over time as they vest, aligning part of his compensation with ProQR’s long-term share performance.
ProQR Therapeutics N.V. director and Chief Scientific Officer Gerardus Johannes Platenburg has filed an initial statement of beneficial ownership. The filing lists direct holdings of 824,388 Ordinary Shares.
It also details multiple option grants to buy Ordinary Shares at exercise prices ranging from $0.6700 to $15.7800, with expiration dates between 2026-12-31 and 2035-12-31. Footnotes explain that some options are fully vested, while others vest 25% on specific January 1 dates from 2024 through 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to his continuous service.
The transaction summary shows holding entries only, with no reported purchases, sales, exercises, gifts, or tax-withholding dispositions in this filing.
ProQR Therapeutics N.V. director Martin Alexander Maier reported his holdings of share options that give him the right to buy Ordinary Shares at fixed prices. The filing lists several option grants with exercise prices between $1.02 and $3.41 per share and expirations from 2032 through 2035.
The derivative positions include options over 500 Ordinary Shares at an exercise price of $1.02 expiring on February 29, 2032, and additional options over 500 shares at $3.41 and 500 shares at $1.98. Larger grants cover 14,186 shares at $1.90, 22,128 shares at $2.65, and 25,192 shares at $2.02, with staggered expiration dates. Footnotes explain that some options are fully vested, while others vest 25% on specified dates such as January 1, 2024, January 1, 2025, May 22, 2025, January 1, 2026, and January 1, 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to his continuous service.